Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL

Peter HillmenSt James’s Institute of Oncology, Leeds, West Yorkshire, UK; Correspondence[email protected]

Ann JanssensUniversitaire Ziekenhuizen Leuven, Leuven, Belgium;

K. Govind BabuHCG Curie Centre of Oncology, Bangalore, India; ;Kidwai Memorial Hospital, Bangalore, Karnataka, India;

Janusz KloczkoMedical University of Bialystok, Bialystok, Poland;

Sebastian GrosickiDepartment of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland;

Stephanie MansonNovartis Pharmaceuticals, Uxbridge, UK;

Astrid McKeownNovartis Pharmaceuticals, Uxbridge, UK;

Ira GuptaNovartis Pharmaceuticals, King of Prussia, PA, USA;

Chai-Ni ChangNovartis Pharmaceuticals, King of Prussia, PA, USA;

Fritz OffnerUniversitair Ziekenhuis Gent, Ghent, Belgium

Your download is now in progress and you may close this window